The available experimental and clinical data still leave many unanswered questions concerning the role of digitalis therapy after acute myocardial infarction. 
SUMMARY
The available experimental and clinical data still leave many unanswered questions concerning the role of digitalis therapy after acute myocardial infarction. It seems clear that little is to be gained by glycoside administration to patients with uncomplicated infarctions who do not have cardiomegaly. The precise role of digitalis therapy in the treatment of cardiogenic shock remains undefined on the basis of the available data. However, until evidence to the contrary appears, its use should be continued on the basis of experience with experimental cardiogenic shock and the presumption that this state, when observed clinically, is a form of extreme left ventricular failure.
Digitalis appears to be indicated in the treatment of atrial fibrillation with rapid ventricular rate complicating acute myocardial infarction. Other supraventricular arrhythmias, such as atrial flutter and ectopic atrial tachycardia, frequently require larger doses of the glycoside, and other means of therapy, such as antiarrhythmic agents or electrical conversion, may be preferable in such instances.
Digitalis is commonly utilized early in the treatment of congestive heart failure and cardiomegaly complicating acute myocardial infarction, despite the paucity of experimental and clinical evidence in support of such therapy. Whether the digitalis glycosides should continue to be used routinely in such patients is an important subject for clinical investigation. ALTHOUGH DIGITALIS therapy in pa-14, tients with acute myocardial infarction has been advocated since the original systematic account in English of this syndrome by Herrick in 1912,1 considerable controversy concerning the indications and usefulness of digitalis in such patients still exists. In recent years substantial information regarding the mechanisms of action of digitalis glycosides has accumulated, and it is the purpose of this lowers the abnormally elevated left ventricular end-diastolic pressure.2 5 In patients in whom myocardial infarction has eliminated significant quantities of myocardium from contributing to the contractile process, cardiac output can be sustained only by an increased extent of shortening of the surviving myocardium, some of which may be ischemic but much of which is adequately perfused and may in fact be normal.6 For this reason it is pertinent to consider the action of cardiac glycosides both on normal, nonischemic heart muscle and on ischemic myocardium.
Considerable information concerning the action of digitalis glycosides on the nonfailing heart is now available.7 The contractile force of the nonfailing right ventricle of anesthetized patients undergoing cardiopulmonary bypass for correction of atrial septal defect or pulmonic stenosis was found to be augmented strikingly by the administration of intravenous acetylstrophanthidin.8 Similarly, in conscious subjects with atrial septal defect, in whom the hemodynamic burden placed on the left ventricle presumably is normal, administration of intravenous ouabain significantly augmented the rate of rise of left ventricular pressure (dp/ dt).9 In the absence of concurrent changes of heart rate, left ventricular end-diastolic pressure, or systemic arterial pressure, the observed increases in left ventricular dp/dt produced by the glycoside may be considered to reflect a true improvement in myocardial contractility.
Recent investigations have suggested that the concepts derived from skeletal muscle mechanics'0 can be effectively utilized in the analysis of cardiac function." This approach makes use of the finding that at any given ventricular end-diastolic volume (myocardial fiber length), there is an inverse relation between the force of muscle contraction, i.e., the load the muscle can lift, and its velocity of shortening. The postition of the curve relating these two variables, the force-velocity curve, serves as a useful and sensitive index of the inotropic state of the myocardium. In order to utilize this approach for studying the effects of cardiac glycosides on the function of nonfailing, nonischemic heart muscle, cineradiograms of roentgen-opaque markers sutured to the external surfaces of the ventricles of patients who had undergone corrective cardiac operations were obtained. The velocity of movement of these markers was compared to the simultaneously recorded intraventricular pressure, and the resultant calculated forcevelocity relation indicated again that ouabain augmented contractility of the nonfailing, nonischemic human myocardium.12 This conclusion is also supported by the observation that the drug lowers the postexercise oxygen debt in patients with cardiomegaly but without heart failure.'3 From these clinicopharmacologic studies it appears that, even though cardiac glycosides have little effect on the pumping action of the normal ventricle as expressed in the cardiac output,'4 they do exert a stimulating influence on normal cardiac muscle. This action provides a theoretic basis for the possible beneficial action of the drug in patients with myocardial infarction in whom the surviving normal myocardium must sustain the entire contractile effort.
B. Hypoxic Myocardium
It is essential also to consider the effects of the cardiac glycosides on hypoxic myocardium. Hypoxia of surviving myocardium occurs for a number of reasons in patients with acute myocardial infarction. First of all, systemic hypoxemia is common in these patients and it is presumably related to impaired pulmonary gas exchange, as a consequence of the elevated pulmonary capillary pressure, resulting from impairment of left ventricular performance.15-19 A second important mechanism responsible for myocardial hypoxia is related to the relatively large zone of heart muscle surrounding an infarct which receives a portion of its blood supply from the occluded coronary vessel.20 The oxygen available to this portion of myocardium, which Edwards21 has aptly termed the "twilight zone," is reduced to a varying extent, although not totally eliminated. A third cause of myocardial hypoxia in patients with acute Circulation, Volume XLV, April 1972 DIGITALIS TREATMENT OF MI infarction is arteriosclerotic narrowing in the unoccluded coronary vessels. Coronary arteriosclerosis is a diffuse disease, and segments of myocardium quite remote from the acute infarct may also suffer from an impairment of oxygen delivery resulting from coronary arterial stenosis, particularly during hypotensive episodes.
The effect of acetylstrophanthidin on ischemic myocardium was studied by Sarnoff and co-workers in an isolated heart preparation in which aortic pressure, heart rate, and stroke volume were held constant.22 Even when coronary flow was reduced to 30% of control values, direct coronary injection of acetylstrophanthidin produced a marked increase in contractility without significant changes in myocardial oxygen consumption or external efficiency. In studies carried out on dogs rendered hypoxic by breathing 7-10% oxygen without coronary occlusion, Donlon and Yu reported an average rise of 25% in left ventricular dp/dt and a mean increase of 34% in stroke work after acetylstrophanthidin, without a consistent change in left ventricular diastolic pressure.23 In nonhypoxic animals given intravenous acetylstrophanthidin, the comparable increments in left ventricular dp/dt and stroke work were 84 and 40%, respectively. These data suggest that the response of hypoxic myocardium to digitalis, while attenuated, is not abolished.
From the above experimental observations it appears that the contraction of ischemic myocardium can be stimulated acutely by positive inotropic agents, including the digitalis glycosides. As will be evident, however, this enhancement of contractility may, under certain circumstances, exert a deleterious effect. In this connection, the effects of hypoxia may be of importance in Recently, the effects of a variety of agents, including digitalis, on the extent and severity of ischemic injury in dogs with acute coronary occlusion were evaluated by use of an epicardial mapping technique.33 In dogs without ventricular enlargement or impaired performance, ouabain increased the severity and extent of the ischemic injury. In contrast, in animals with coronary occlusion and pharmacologically induced heart failure and ventricular dilatation, identical doses of the glycoside tended to reduce the extent and severity of ischemic damage.34 It is postulated that the fate of the periinfarction zone, with the limited oxygen available to it, is influenced profoundly by the 02 requirements of the tissue. Increasing the latter in the nonfailing heart, by means of ouabain and other inotropic stimuli such as isoproterenol, intensifies ischemia, resulting ultimately in more extensive infarction. In contrast, reducing myocardial 02 demands, by administering digitalis to the failing heart, or by means of synchronized aortic balloon counterpulsation,34 evidently allows for survival of the underperfused zone bordering the infarct.
Several investigators have studied the effects of digitalis on overall cardiac performance in experimental myocardial infarction. In anesthetized dogs studied several days after acute experimental myocardial infarction, Hood et al. demonstrated no improvement of cardiac performance after acetylstrophanthidin, as judged by the relationship between left ventricular filling pressure and cardiac output.35 Moreover, in the unanesthetized dog with an elevated left ventricular end-diastolic pressure and a reduced stroke volume studied 1 hour after acute myocardial infarction, ouabain did not cause a beneficial hemodynamic change.36 Seven days later, however, during the healing phase of acute infarction, acetylstrophanthidin caused a reduction of left ventricular end-diastolic pressure and an elevation of stroke volume and cardiac output.36 Thus, in experimentally produced acute myocardial infarction, the effects of digitalis on cardiovascular dynamics appear to depend upon the timing of its administration in relation to the infarction and its effect on the extent and severity of myocardial ischemic injury. The latter is related to the degree of impairment of cardiac function and the attendant degree of cardiomegaly.
Effects of Catecholamine Depletion
It has been demonstrated that cardiac catecholamine depletion is a biochemical hallmark of chronic congestive cardiac failure.37 In experimental canine myocardial infarction, norepinephrine cannot be detected after the second day in the infarcted area.38 In addition, uninvolved left ventricular muscle exhibits a rapid decline in norepinephrine stores, which reaches its nadir by the tenth day.38 Although it has been postulated repeatedly that the inotropic action of digitalis is dependent on cardiac norepinephrine stores,39-42 there is now abundant evidence that catecholamine depletion or adrenergic blockade does not diminish the positive inotropic effects of digitalis preparations.43 44 Therefore, the absence of prominent hemodynamic effects of digitalis in myocardial infarction should not be attributed to catecholamine depletion. The specific digitalis preparation recommended differs according to the circumstance.
For urgent situations, such as acute pulmonary edema complicating myocardial infarction, ouabain has been suggested. 71 74,76 Because of its rapidity of onset and dissipation and the ease of dosage adjustment, Lown and associates also advocate ouabain as the preparation of choice.76 Logue and Hurst, on the other hand, have indicated that switching to other preparations for maintenance therapy may pose a problem; hence, they favor the use of digoxin.75 If digitalis is to be used in the therapy of acute myocardial infarction, it might be best for the individual clinician to prescribe the preparation with which he is most familiar. The potential hazard of bolus intravenous injections of rapidly acting glycosides has already been commented upon.
As indicated earlier, animal studies do not support the concept that the patient with acute myocardial infarction is more susceptible to the arrhythmogenic properties of the glycosides in the usual dose range.5860 Prior to the advent of routine cardiac monitoring in the coronary care unit, Askey treated 50 patients with uncomplicated myocardial infarction with digitoxin and noted no difference in the incidence of ventricular ectopic beats or of sudden death in this group compared with a control group of 50 untreated subjects.63 It is likely that any increase in susceptibility to digitalis toxicity relates to the severity of the 
